TrialJournal for immunotherapy of cancer2020

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.

Ami N Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.